{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stein A"],"funding":["European Hematology Association","Universitätsklinikum Leipzig"],"pagination":["55"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9649510"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["117(1)"],"pubmed_abstract":["Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by increasing all-cause mortality by 40%. This is due predominantly to a nearly two-fold increase of cardiovascular risk, but also to an elevated risk of malignant transformation. Individuals with CH show not only increased risk for, but also worse outcomes after arteriosclerotic events, such as stroke or myoc"],"journal":["Basic research in cardiology"],"pubmed_title":["Clonal hematopoiesis and cardiovascular disease: deciphering interconnections."],"pmcid":["PMC9649510"],"funding_grant_id":["RG11","CRTH1","TRTH1"],"pubmed_authors":["Cross M","Stein A","Platzbecker U","Buettner P","Rommel KP","Rosolowski M","Thiele H","Kubasch AS","Desch S","Metzeler K"],"additional_accession":[]},"is_claimable":false,"name":"Clonal hematopoiesis and cardiovascular disease: deciphering interconnections.","description":"Cardiovascular and oncological diseases represent the global major causes of death. For both, a novel and far-reaching risk factor has been identified: clonal hematopoiesis (CH). CH is defined as clonal expansion of peripheral blood cells on the basis of somatic mutations, without overt hematological malignancy. The most commonly affected genes are TET2, DNMT3A, ASXL1 and JAK2. By the age of 70, at least 20-50% of all individuals carry a CH clone, conveying a striking clinical impact by increasing all-cause mortality by 40%. This is due predominantly to a nearly two-fold increase of cardiovascular risk, but also to an elevated risk of malignant transformation. Individuals with CH show not only increased risk for, but also worse outcomes after arteriosclerotic events, such as stroke or myoc","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-05-29T16:11:53.194Z","creation":"2025-04-04T09:32:19.588Z"},"accession":"S-EPMC9649510","cross_references":{"pubmed":["36355225"],"doi":["10.1007/s00395-022-00969-w"]}}